Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]AlF-NODA-C6-CTHRSSVVC
- Development stage
- Unknown
- Lead developer
- University Medical Center Groningen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[18F]AlF-NODA-C6-CTHRSSVVC (also studied as [18F]AlF-NODA-MP-C6-CTHRSSVVC) is a positron emission tomography (PET) radiotracer developed for imaging tumor-associated macrophages (TAMs), specifically targeting the CD163 receptor expressed on M2-type macrophages. The tracer consists of the synthetic peptide CTHRSSVVC, which mimics the CD163 and TNF-α tripeptide "RSS" motif, conjugated to a NODA-MP-C6 chelator and radiolabeled with aluminum [18F]fluoride ([18F]AlF). It was developed by researchers at the University Medical Center Groningen (UMCG) in collaboration with the Pontifical Catholic University of Rio Grande do Sul (PUCRS). Preclinical studies in tumor-bearing mice have demonstrated that the tracer can visualize CD163-positive tumor-infiltrating macrophages, with tumor uptake correlating with CD163 expression levels.
- Other names
- [18F]AlF-NODA-MP-C6-CTHRSSVVCNODA-C6-CTHRSSVVCNODA-C-6-CTHRSSVVCNODA-C 6-CTHRSSVVCNODA-MP-C6-CTHRSSVVCNODA-MP-C-6-CTHRSSVVCNODA-MP-C 6-CTHRSSVVC
02
Targets
CD163 (Scavenger receptor cysteine-rich type 1 protein M130)
Beyond the preview
Go deeper on [18F]AlF-NODA-C6-CTHRSSVVC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]AlF-NODA-C6-CTHRSSVVC.